natgillin/translations-raw huggingface dataset:
In the study of ovarian, fallopian tube and peritoneal cancer that came back 6 month or more after previous chemotherapy, average progression-free survival was 12.4 months when Avastin was added to carboplatin and gemcitabine, compared with 8.4 months when placebo was added.
V študiji raka jajčnikov, jajcevodov in potrebušnice, ki se je ponovno pojavil šest ali več mesecev po opravljeni kemoterapiji, je povprečni čas preživetja brez napredovanja bolezni pri dodajanju zdravila Avastin karboplatinu in gemcitabinu znašal 12,4 meseca, pri dodajanju placeba pa 8,4 meseca.
In the study of patients already being treated with an epoetin, haemoglobin levels were maintained at around 11.4 g/dl when the patients were receiving Silapo and when they were receiving Eprex/Erypo.
V študiji pri bolnikih, ki so se že zdravili z epoetinom, so ravni hemoglobina ostale na ravni približno 11,4 g/dl, kadar so bolniki prejemali zdravilo Silapo in kadar so prejemali zdravilo Eprex/Erypo.
In the study of patients undergoing hip replacement, blood clots were detected in 6% of the patients taking 220 mg Pradaxa (50 out of 880), compared with 7% of the patients receiving enoxaparin (60 out of 897).
V študiji z bolniki, ki so jim operativno vstavili umetni kolk, so krvne strdke odkrili pri 6 % (50 od 880) bolnikov, ki so prejemali 220-miligramski odmerek zdravila Pradaxa, v primerjavi s 7 % (60 od 897) bolnikov, ki so prejemali enoksaparin.
In the study of patients undergoing knee replacement, blood clots were detected in 36% of the patients taking the 220 mg dose of Pradaxa (182 out of 503), compared with 38% of the patients receiving enoxaparin (192 out of 512).
V študiji z bolniki, ki so jim operativno vstavili umetno koleno, so krvne strdke odkrili pri 36 % (182 od 503) bolnikov, ki so prejemali 220-miligramski odmerek zdravila Pradaxa, v primerjavi z 38 % (192 od 512) bolnikov, ki so prejemali enoksaparin.
In the study of patients who had been treated before, the patients taking lopinavir had larger reductions in viral loads over the first 48 weeks.
V študiji z bolniki, ki so se zaradi okužbe s HIV že zdravili, so v prvih 48 tednih opazili večja zmanjšanja virusnega bremena pri bolnikih, ki so jemali lopinavir.
In the study of patients whose spleen had been removed, 38% of the patients had a lasting response to treatment with Nplate (16 out of 42), compared with none of the 21 patients receiving placebo.
V študiji z bolniki z odstranjeno vranico je 38 % (16 od 42) bolnikov doseglo trajen odziv na zdravilo Nplate v primerjavi z nobenim od 21 bolnikov, ki so prejemali placebo.
In the study of patients with a single demyelinating event, Betaferon was shown to reduce the risk of developing clinically defined MS: 28% of the patients who received Betaferon developed MS, compared with 45% of those who received placebo.
V študiji pri bolnikih z enkratnim demielinizacijskim dogodkom so ugotovili, da je zdravilo Betaferon zmanjšalo tveganje za razvoj klinično potrjene multiple skleroze: ta se je razvila pri 28 % bolnikov, ki so prejemali zdravilo Betaferon, v primerjavi s 45 % tistih, ki so prejemali placebo.
In the study of patients with a single demyelinating event, Extavia was shown to reduce the risk of developing clinically defined MS: 28% of the patients who received Extavia developed MS, compared with 45% of those who received placebo.
V študiji z bolniki z enkratnim demielinizacijskim dogodkom so ugotovili, da je zdravilo Extavia zmanjšalo tveganje za razvoj klinično dokončne multiple skleroze: ta se je razvila pri 28 % bolnikov, ki so prejemali zdravilo Extavia, v primerjavi s 45 % tistih, ki so prejemali placebo.
In the study of patients with advanced Parkinson’s disease, patients taking Mirapexin immediate- release tablets had larger improvements after 24 weeks of steady-dose treatment than those taking placebo.
V študiji z bolniki z napredovalo Parkinsonovo boleznijo je bilo pri bolnikih, ki so jemali tablete Mirapexin s podaljšanim sproščanjem, po 24 tednih zdravljenja s stalnim odmerkom doseženo večje izboljšanje kot pri bolnikih, ki so jemali placebo.
In the study of patients with advanced Parkinson’s disease, patients taking Sifrol immediate-release tablets had larger improvements after 24 weeks of steady-dose treatment than those taking placebo.
V študiji z bolniki z napredovalo Parkinsonovo boleznijo je bilo pri bolnikih, ki so jemali tablete Sifrol s podaljšanim sproščanjem, po 24 tednih zdravljenja s stalnim odmerkom doseženo večje izboljšanje kot pri bolnikih, ki so jemali placebo.
In the study of patients with anaemia caused by kidney problems, patients switching to Abseamed maintained haemoglobin levels to the same extent as those continuing to take Eprex/Erypo.
V študiji pri bolnikih z anemijo, ki jo povzročajo obolenja ledvic, so ravni hemoglobina pri osebah, ki so prešle na zdravilo Abseamed, ostale na isti ravni kot pri tistih, ki so še naprej prejemale zdravilo Eprex/Erypo.
In the study of patients with anaemia caused by kidney problems, patients switching to Binocrit maintained haemoglobin levels to the same extent as those continuing to take Eprex/Erypo.
V študiji pri bolnikih z anemijo, ki jo povzročajo obolenja ledvic, so ravni hemoglobina pri osebah, ki so prešle na zdravilo Binocrit, ostale na isti ravni kot pri tistih, ki so še naprej prejemale zdravilo Eprex/Erypo.
In the study of patients with anaemia caused by kidney problems, patients switching to Epoetin Alfa Hexal maintained haemoglobin levels to the same extent as those continuing to take Eprex/Erypo.
V študiji pri bolnikih z anemijo, ki jo povzročajo obolenja ledvic, so ravni hemoglobina pri osebah, ki so prešle na zdravilo Epoetin Alfa Hexal, ostale na isti ravni kot pri tistih, ki so še naprej prejemale zdravilo Eprex/Erypo.
In the study of patients with progressive MS, Rebif had no significant effect on the progression of disability, but the relapse rate was reduced by about 30%.
V študiji z bolniki s progresivno multiplo sklerozo zdravljenje z zdravilom Rebif ni imelo večjega vpliva na napredovanje nesposobnosti, vendar se je stopnja zagonov znižala za približno 30 %.
In the study of rheumatoid arthritis patients with an inadequate response to TNF blockers in the past, adding Orencia to existing treatment led to 50% of the patients having a reduction in symptoms (129 out of 256) after 6 months, compared with 20% of the patients adding placebo (26 out of 133).
V študiji, v kateri so proučevali bolnike z revmatoidnim artritisom, ki se v preteklosti niso ustrezno odzvali na zaviralce TNF, je dodajanje zdravila Orencia obstoječemu zdravljenju prispevalo k zmanjšanju simptomov pri 50 % (129 od 256) bolnikov v primerjavi z 20 % (26 od 133) tistih, ki so kot dodatek prejemali placebo.
In the study of smoke inhalation, the response to Cyanokit was assessed as ‘positive’ in 31 patients (45%), ‘partial’ in 15 (22%) and ‘absent’ in 10 (15%).
V študiji vdihavanja dima so odziv na zdravilo Cyanokit pri 31 (45 %) bolnikih ocenili kot „pozitiven“, pri 15 (22 %) bolnikih kot „delen“ in pri 10 (15 %) bolnikih kot „odsoten“.
In the study of Tarceva used in combination with gemcitabine for pancreatic cancer, the most common side effects were tiredness (seen in 73% of patients), rash (seen in 69% of patients) and diarrhoea (seen in 48% of patients).
V študiji z zdravilom Tarceva, uporabljenem v kombinaciji z gemcitabinom za zdravljenje raka trebušne slinavke, so bili najpogostejši neželeni učinki utrujenost (opažena pri 73 % bolnikov), izpuščaji (opaženi pri 69 % bolnikov) in driska (opažena pri 48 % bolnikov).
In the study of type 1 Gaucher disease, there were moderate reductions in the size of the liver (12% reduction) and the spleen (19% reduction) after a year.
V študiji Gaucherjeve bolezni tipa 1 je po enem letu prišlo do zmernega zmanjšanja velikosti jeter (12– odstotno zmanjšanje) in vranice (19–odstotno zmanjšanje).
In the study on newly diagnosed Ph+ patients with chronic phase CML, Sprycel was more effective than imatinib: within one year, 77% of patients receiving Sprycel no longer had the Philadelphia chromosome in their blood cells, compared with 66% of patients receiving imatinib.
V študiji bolnikov, pri katerih so na novo ugotovili KML v kroničnem obdobju s prisotnim kromosomom Philadelphia, je bilo zdravilo Sprycel učinkovitejše od imatiniba: v enem letu 77 % bolnikov, ki so prejemali zdravilo Sprycel, v krvnih celicah ni imelo več kromosoma Philadelphia, v primerjavi s 66 % bolnikov, ki so prejemali imatinib.
In the study where saxagliptin was taken in addition to insulin (with or without metformin), HbA1c levels fell by around 0.7%, compared with a decrease of around 0.3% in patients who took placebo with insulin.
V študiji, v kateri se je saksagliptin jemal poleg insulina (skupaj z metforminom ali brez njega), so se ravni HbA1c znižale za okoli 0,7 % v primerjavi z okoli 0,3-odstotnim znižanjem pri bolnikih, ki so jemali placebo z insulinom.
In the study, apixaban achieved statistically significant superiority in the primary endpoint of prevention of stroke (haemorrhagic or ischaemic) and systemic embolism (see Table 4) compared with warfarin.
V študiji se je apiksaban izkazal kot statistično pomembno boljše zdravilo glede primarnega opazovanega dogodka - preprečevanja možganske kapi (hemoragične, ishemične ali neopredeljene) ali sistemske embolije (glejte Preglednico 6) v primerjavi z acetilsalicilno kislino.
In the study, apixaban was shown to be non-inferior to enoxaparin/warfarin in the combined primary endpoint of adjudicated recurrent symptomatic VTE (nonfatal DVT or nonfatal PE) or VTE-related death (see Table 10).
V študiji se je pokazalo, da je pri sestavljenem primarnem opazovanem dogodku - ponovna simptomatska VTE (GVT brez smrtnega izida ali PE brez smrtnega izida) ali z VTE povezana smrt - apiksaban enakovreden zdravljenju z enoksaparinom/varfarinom (glejte Preglednico 10).
In the study, apixaban was shown to be non-inferior to enoxaparin/warfarin in the combined primary endpoint of adjudicated recurrent symptomatic VTE (nonfatal DVT or nonfatal PE) or VTE-related death (see Table 8).
V študiji sta bila oba odmerka apiksabana pri primarnem opazovanem dogodku - ponovna simptomatska VTE (GVT brez smrtnega izida ali PE brez smrtnega izida) ali smrt iz vseh vzrokov - statistično superiorna v primerjavi s placebom (glejte Preglednico 10).
In the study, apixaban was statistically superior to enoxaparin/warfarin in the primary safety endpoint [Relative Risk 0.31, 95% confidence interval (0.17, 0.55), P-value <0.0001] (see Table 11).
V študiji je bil apiksaban glede tega statistično superioren v primerjavi z enoksaparinom/varfarinom (relativno tveganje 0,31, 95 % interval zaupanja (0,17, 0,55), vrednost p < 0,0001) (glejte Preglednico 11).
In the study, both doses of apixaban were statistically superior to placebo in the primary endpoint of symptomatic, recurrent VTE (nonfatal DVT or nonfatal PE) or all-cause death (see Table 12).
V študiji sta bila oba odmerka apiksabana pri primarnem opazovanem dogodku - ponovna simptomatska VTE (GVT brez smrtnega izida ali PE brez smrtnega izida) ali smrt iz vseh vzrokov - statistično superiorna v primerjavi s placebom (glejte Preglednico 12).
In the study, Cabometyx was compared with the cancer medicine everolimus.
V tej študiji so zdravilo Cabometyx primerjali z zdravilom everolimus za zdravljenje raka.
In the study, Jinarc was compared with placebo (a dummy treatment) and the main measure of effectiveness was the change in kidney size after 3 years of treatment (a way of measuring the swelling caused by cyst formation).
V študiji so zdravilo Jinarc primerjali s placebom (zdravilom brez zdravilne učinkovine), glavno merilo učinkovitosti pa je bilo sprememba velikosti ledvic po treh letih zdravljenja (način merjenja otekanja, ki ga povzroča nastajanje cist).
In the subcutaneous fertility study in rats, while no effects were reported in males, in females, fertility was impaired and a NOAEL (no observed adverse effect level) of 5 mg/kg was identified.
V študiji plodnosti pri podganah pri subkutanem odmerjanju pri samcih niso poročali o nikakršnih učinkih, pri samicah pa je bila plodnost zmanjšana, odmerek, pri katerem niso opazili neželenih učinkov, pa je bil 5 mg/kg.
In the subgroup aged > 65 years the percentage of vaccinees with rSBA titres ≥ 128 at one month post- vaccination ranged from 90% (group A) to 97% (group Y).
V podskupini, stari > 65 let, je delež cepljenih oseb s titrom rSBA ≥ 128 en mesec po cepljenju znašal od 90 % (proti skupini A) do 97 % (proti skupini Y).
In the subgroup aged > 65 years the percentage of vaccinees with rSBA titres ≥ 128 at one month post-vaccination ranged from 90% (group A) to 97% (group Y).
V podskupini, stari > 65 let, je delež cepljenih oseb s titrom rSBA ≥ 128 en mesec po cepljenju znašal od 90 % (proti skupini A) do 97 % (proti skupini Y).
In the subgroup analyses of prior cisplatin use versus BSC for progression free survival (PFS), the results were: HR (95% CI) = [0.55 (0.34 – 0.89); p=0.0129] in the absence of prior cisplatin, and a HR (95% CI) = [0.64 (0.48 – 0.85); p=0.0040] in the presence of prior cisplatin.
V analizah podskupin s predhodnim zdravljenjem s cisplatinom in NPO za preživetje brez napredovanja bolezni so bili rezultati: HR (95- odstotni IZ) = [0,55 (0,34 – 0,89); p=0,0129] brez predhodnega cisplatina in HR (95-odstotni IZ) = [0,64 (0,48 – 0,85); p=0,0040] po predhodno uporabljenem cisplatinu.
In the subgroup of patients with an APACHE II score ≥25 at baseline, the mortality was 31% in the Xigris group (128 out of 414) and 44% in the placebo group (176 out of 403).
V podskupini bolnikov s številom točk po APACHE II  25 ob izhodišču je bila umrljivost 31 % v skupini zdravila Xigris (128 od 414) in 44 % v skupini placeba (176 od 403).
In the subgroup of patients with HR ≥ 75 bpm (n=4150), a greater reduction was observed in the primary composite endpoint of 24 % (hazard ratio: 0.76, 95%CI [0.68;0.85] – p<0.0001) and for other secondary endpoints, including all cause death (hazard ratio: 0.83, 95%CI [0.72;0.96] – p=0.0109) and CV death (hazard ratio: 0.83, 95%CI [0.71;0.97] – p=0.0166).
V podskupini bolnikov s srčno frekvenco ≥ 75 utripov na minuto (n=4150) je bilo opazno večje zmanjšanje primarnega končnega izida za 24 % (razmerje tveganja: 0,76, 95 % interval zaupanja [0,68; 0,85] – p<0,0001) in drugih sekundarnih končnih izidov, vključno z umrljivostjo zaradi različnih vzrokov (razmerje tveganja: 0,83, 95 % interval zaupanja [0,72; 0,96] – p=0,0109) in srčno-žilno umrljivostjo (razmerje tveganja: 0,83, 95 % interval zaupanja [0,71; 0,97] – p=0,0166).
In the subgroup of patients with non-measurable disease (n=205), based on IRC assessments, the hazard ratios for PFS and OS were 0.91 (95% CI: 0.59, 1.42) and 0.96 (95% CI: 0.54, 1.68), respectively.
V podskupini bolnikov z nemerljivo boleznijo (n = 205) je bilo na podlagi ocen IRC razmerje ogroženosti za PFS 0,91 (95-% interval zaupanja: 0,59 do 1,42) in za celokupno preživetje 0,96 (95-% interval zaupanja: 0,54 do 1,68).
In the subpopulation of patients receiving glucocorticoids for more than 3 months prior to randomisation, zoledronic acid increased lumbar spine BMD by 4.06% versus 2.71% for risedronate (mean difference: 1.36% ; p<0.001).
V podskupini bolnikov, ki so prejemali glukokortikoide več kot 3 mesece pred randomizacijo, je zoledronska kislina povečala mineralno gostoto kosti ledvene hrbtenice za 4,06 % v primerjavi z 2,71 % pri uporabi risedronata (z razliko povprečij: 1,36 %; p <0,001).
In the subpopulation of patients that had received glucocorticoids for 3 months or less prior to randomisation, zoledronic acid increased lumbar spine BMD by 2.60% versus 0.64% for risedronate (mean difference: 1.96% ; p<0.001).
V podskupini bolnikov, ki so prejemali glukokortikoide 3 mesece ali manj pred randomizacijo, je zoledronska kislina povečala mineralno gostoto kosti ledvene hrbtenice za 2,60 % v primerjavi z 0,64 % pri uporabi risedronata (z razliko povprečij: 1,96 %; p < 0,001).
In the subpopulation of patients that had received glucocorticoids for 3 months or less prior to randomisation, zoledronic acid increased lumbar spine BMD by 2.60% versus 0.64% for risedronate (mean difference: 1.96% ; p<0.001).
V podskupini bolnikov, ki so prejemali glukokortikoide 3 mesece ali manj pred randomizacijo, je zoledronska kislina povečala mineralno gostoto kosti ledvene hrbtenice za 2,60 % v primerjavi z 0,64 % pri uporabi risedronata (z razliko povprečij: 1,96 %; p <0,001).
In the subpopulation of patients that had received glucocorticoids for 3 months or less prior to randomisation, zoledronic acid increased lumbar spine BMD by 2.60% versus 0.64% for risedronate (mean difference: 1.96%; p<0.001).
V podskupini bolnikov, ki so prejemali glukokortikoide 3 mesece ali manj pred randomizacijo, je zoledronska kislina povečalo mineralno gostoto kosti ledvene hrbtenice za 2,60 % v primerjavi z 0,64 % pri uporabi risedronata (z razliko povprečij: 1,96 %; p < 0,001).
In the subset of 6 children aged 3 – 5 who were compliant with their drug regimen, the mean AUC was 147 M·h, which was 23 % lower than expected.
V podskupini 6 otrok, starih 3 - 5 let, ki so zdravilo dobivali v skladu z navodili, je bil povprečni AUC 147 M∙h, kar je bilo 23 % manj od pričakovanega.
In the subset of patients (5.2%) with the highest antibody concentrations, the mean improvement in HbA1c at Week 24 and at Week 76 was in a clinically relevant range; however there was variability in the glycaemic response and 1.9% had no decrease in HbA1c.
V podskupini bolnikov (5,2 %) z najvišjo koncentracijo protiteles je bilo povprečno izboljšanje HbA1c 24. in 76. teden v klinično pomembnem območju, obstajala pa je variabilnost, kar zadeva glikemičen odziv in pri 1,9 % bolnikov ni bilo znižanja HbA1c.
In the subset of patients (5.2%) with the highest antibody concentrations, the mean improvement in HbA1c at Week 24 and at Week 76 was in a clinically relevant range; however there was variability in the glycaemic response and 1.9% had no decrease in HbA1c.
V podskupini bolnikov (5,2 %) z najvišjo koncentracijo protiteles je bilo povprečno izboljšanje HbA1c 24. in 76. tednu v klinično pomembnem območju, obstajala pa je variabilnost, kar zadeva glikemičen odziv in pri 1,9% bolnikov ni bilo znižanja HbA1c.
In the subset of patients with a medical history of elevated transaminases, increased ALT or AST have been reported more frequently in patients receiving ivacaftor compared to placebo.
V podskupini bolnikov z medicinsko anamnezo zvišanih transaminaz so pogosteje poročali o zvišani ALT ali AST pri bolnikih, ki so prejemali ivakaftor, kot pri placebu.
In the subset of subjects aged 11-18 years who were seronegative at baseline (hSBA < 1:4), the proportion of subjects who achieved a hSBA ≥ 1:8 after a dose of Menveo were as follows: serogroup A 75% (780/1039); serogroup C 80% (735/923); serogroup W135 94% (570/609); serogroup Y 81% (510/630).
Pri osebah, starih 11-18 let, ki so bile ob izhodišču seronegativne (hSBA <1:4), je bil delež oseb, ki so po prvem odmerku cepiva Menveo dosegle hSBA ≥ 1:8, kot sledi: seroskupina A 75 % (780/1039); seroskupina C 80 % (735/923); seroskupina W135 94 % (570/609); seroskupina Y 81 % (510/630).
In the subset of subjects aged 19-55 years who were seronegative at baseline, the proportion of subjects who achieved a hSBA ≥ 1:8 after a dose of Menveo were as follows: serogroup A 67% (582/875); serogroup C 71% (401/563); serogroup W135 82% (131/160); serogroup Y 66% (173/263).
Pri osebah, starih 19-55 let, ki so bile ob izhodišču seronegativne, je bil delež oseb, ki so po prvem odmerku cepiva Menveo dosegle hSBA ≥ 1:8, kot sledi: seroskupina A 67 % (582/875); seroskupina C 71 % (401/563); seroskupina W135 82 % (131/160); seroskupina Y 66 % (173/263).
In the substudy of study VI, patients who had achieved remission at 2 years (DAS 28 ESR < 2.6) and after at least 1 year of treatment with abatacept in Study VI were eligible to enter a substudy.
V podštudijo študije VI so bili vključeni bolniki, ki so glede na doseženo remisijo po 2 letih (DAS 28 sedimentacija eritrocitov < 2,6) in zdravljenje z abataceptom v študiji VI vsaj 1 leto, bili primerni za vključitev v podštudijo.
in the syringe, hold the syringe with the needle pointing upwards and gently flick the syringe until all the air collects at the top.
mehurčke zraka v brizgi, jo držite tako, da igla gleda navzgor in nežno krcajte brizgo, da se ves zrak zbere na vrhu.
in the syringe, hold the syringe with the needle pointing upwards and gently flick the syringe until all the air collects at the top.
mehurčke: če vidite mehurčke zraka v brizgi, jo držite tako, da igla gleda navzgor in nežno krcajte brizgo, da se ves zrak zbere na vrhu.
In the table below (Table 1) all adverse reactions are presented by System Organ Class and frequency.
V spodnji preglednici (preglednica 1) so vsi neželeni učinki predstavljeni po organskih sistemih in pogostnosti.
In the table below all adverse reactions are listed by system organ class and by frequency.
V spodnji preglednici so navedeni vsi neželeni učinki glede na prizadeti organski sistem in pogostnost.
In the table below all adverse reactions, which occurred at an incidence greater than placebo and numerically present in more than 1 patient are listed by System Organ Class and frequency: very common ≥1/10, common ≥1/100 to <1/10, uncommon ≥1/1,000 to <1/100, rare ≥1/10,000 to <1/1,000.
V spodnji preglednici so neželeni učinki, ki so bili pogostejši kot pri jemanju placeba in ki so se pojavili pri več kot enem bolniku, navedeni po organskih sistemih in pogostnosti: zelo pogoste ≥ 1/10, pogoste ≥ 1/100 do < 1/10, občasne ≥ 1/1.000 do < 1/100, redke ≥ 1/10.000 do
In the table below all adverse reactions, which occurred at an incidence greater than placebo are listed by system organ class and frequency (very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100) and rare (≥ 1/10,000 to < 1/1,000)).
Vsi neželeni učinki, ki so se pojavili z večjo pojavnostjo kot pri placebu, so v spodnji preglednici navedeni po organskem sistemu in pogostnosti (zelo pogosti (≥ 1/10), pogosti (≥ 1/100, < 1/10), občasni (≥ 1/1.000, < 1/100) in redki (≥ 1/10.000, < 1/1.000).
In the table below all adverse reactions, which occurred at an incidence greater than placebo are listed by system organ class and frequency (very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100) and rare (≥ 1/10,000 to < 1/1,000).
Vsi neželeni učinki, ki so se pojavili z večjo pojavnostjo kot pri placebu, so v spodnji preglednici navedeni po organskem sistemu in pogostnosti (zelo pogosti (≥ 1/10), pogosti (≥ 1/100, < 1/10), občasni (≥ 1/1.000, < 1/100) in redki (≥ 1/10.000, < 1/1.000).
In the table below all adverse reactions, which were identified based on the review of the full Eslicarbazepine acetate safety database are presented by System Organ Class and frequency.
V spodnji preglednici so vsi neželeni učinki, ugotovljeni pri pregledu celotne zbirke podatkov o varnosti eslikarbazepinacetata, razvrščeni po organskih sistemih in pogostnosti.
In the table below the specific pharmacokinetic enhancer is specified when recommendeations differ.
Če se priporočila razlikujejo, je v spodnji preglednici naveden farmakokinetični ojačevalec.
In the table, write the date when you activated your pen and the date to throw it away 14 days later.
Sem vpišite datum, ko ste peresnik aktivirali, in datum, ko ga morate 14 dni pozneje zavreči.
In the tables undesirable effects are classified according to System Organ Class and frequency.
Neželeni učinki so v preglednicah razvrščeni po organskih sistemih in pogostnosti.
In the tables undesirable effects are classified according to System Organ Class and frequency.
Neželeni učinki so v preglednicah razvrščeniglede na organski sistem in po pogostnosti.